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ABSTRACT
Objective: To investigate the effect of diminazene aceturate (DA) alone or in combination with
either levamisole and/or Vitamin C in albino rats experimentally infected with Tryparwsoma
brucei brucei. Methods: Thirty adult male albino rats, randomly assigned into 6 groups (A-F) of 5
rats each were used. They were either infected with lX106 trypanosomes intraperitoneally (groups
A-E) or uninfected (group F). The different groups were treated respectively as follows: group
A-with 3.5 mglkg DA; group B-3.5 mglkg DA and 7.5 mglkg levamisole; group C-3.5 mglkg DA
and 100 mglkg vitamin C; and group D-3.5 mglkg DA and 7.5 mglkg levamisole and 100 mglkg
vitamin C. Group E was left untreated. Parameters assessed include: rectal temperature, body
weight changes, packed cell volume (PCV), Haemoglobin concentration (Hb), total leucocyte count
(fLC)differential leucocyte count (DLC), parasitaemia, clinical signs and survivability. Results:
Average pre-patent period of 5 days was recorded. Parasites in the blood were cleared in all
treated groups (A-D)within 48 hours post treatment (Pl). Untreated rats in group E died between
25 and 32 days post infection (PI). Relapse was not recorded in all the treated groups (A-D).
The initial reduction in PCV, Hb, TLC and increases in rectal temperature following infection
were reversed by the treatments. The rats that received drug combinations (groups B, C and D)
showed faster and higher recovery rates than the uninfected control and group A. Conclusions:
Levamisole and/or Vitamin C combination with DA were more effective in the treatment of rats
infected with Trypanosoma brucei brucei.
1. Introduction
African animal trypanosomosis is a disease caused by
a group of protozoan haemoflagellate parasites of the
genus Trypanosoma. They produce persistent infection
in the blood and induce profound immunosuppressionltl.
The disease continues to be a major setback of livestock
production in Nigeria despite attempts to control the
disease[2J. It has also been known to affect humans causing
a condition called sleeping sicknesslsl, Currently there
is no effective vaccine against the disease. However, the
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available means to protect and maintain livestock despite
the short comings of these measures include tsetse control
strategies, chemotherapy and chemoprophylaxis and use of
trypanotolerant livestocldsl, In Africa, control relies mainly
on chemotherapy and chemoprophylaxis using salts of three
compouds - diminazene, homidium and isomethamidium[5J.
In Nigeria diminazene aceturate is the most commonly
used therapeutic agent while Isometamidium chloride is
the most commonly used prophylactic agent[6,7J. Despite
this, treatment of trypanosomosis is faced with challenges
of drug resistance due to wrong use of drugs, and presence
of few trypanocides[8,9]. The inability of readily available
drugs to cross the blood-brain barrier and toxicity are also
major concerns in chemotherapy of trypanosomosis[lO,llJ.
The challenge therefore lies in the careful management of
the few trypanocides in order to minimise resistance and
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prolong the usefulness of these drugs[12,13J. Some of these
strategies include sanative pairs[14], combination therapy[15]
and high dose and repeat treatment regimenliel,
Trypanosomosis is associated with generalized
immunosuppression in infected hosts and the efficiency of
the host's immune system is vital in the eventual destruction
of the parasite. It is therefore conceivable that co-
administration of trypanocides with agents known to have
immunostimulatory and antioxidant properties may enhance
their therapeutic activity and efficacy, hence the study.
2. Materials andmethods
2.1. Experimental animals
Thirty adult male albino rats used for this study were
obtained from the breeding colony of the Department of
Zoology, University of Nigeria, Nsukka. They were assigned
into 6 groups of 5 rats each and kept in metal cages in the
laboratory animal unit of the Department of Veterinary
Parasitology and Entomology, University of Nigeria Nsukka.
The rats were fed standard rat feed (Vital feeds®). The rats
were acclimatized for two weeks prior to commencement of
the experiment.
2.2. Trypanosomes
The Trypanosoma brucei (T. brucei) brucei used in this
study was originally isolated from a hunting dog presented
at the Veterinary Teaching Hospital, University of Nigeria
Nsukka. The parasites were identified morphologically[17]
and by the blood incubation infectivity test (BII'I')[18J. They
were maintained in mice from which donor rats were first
infected.
2.3. Experimental drugs
Three drugs used for this experiment include diminazene
aceturate (Trypazenw Pantex Holland), Levamisole
hydrochloride (Eagle Company Korea), and Vitamin C
(Jinling Pharm China).
2.4. Infection ofexperimental rats
Infected blood from the donor rats were obtained from the
retrobulbar plexus via the median canthus of the eye into
sample bottles containing ethylene diamine tetra acetate
(EDTA). Infected blood was then diluted in phosphate
buffered saline (PBS). Each rat was then infected with 1 X 106
trypanosomes suspended in 0.2 mL of PBSintraperitoneally.
2.5. Experimental design
The thirty Sprague Dawley albino rats used were randomly
assigned to six groups (A-F) of five rats each. All rats
in groups A-E were infected with 1 X 106 trypanosomes
intraperitoneally while group F were left as uninfected
control. Rats in group A-D were treated with 3.5 mglkg
diminazene aceturate intramuscularly 7 d post infection
(PI). However, rats in groups B, C and D received further
treatments with levamisole at 7.5 mg/kg body weight
subcutaneously, vitamin C at 100 mg/kg body weight
intraperitoneally and a combination of levamisole and
vitamin C at same doses respectively. Rats in group E were
left untreated as infected control.
2.6. Parameters for assessing efficacy oftreatments
The efficacy of treatments was assessed weekly using the
following parameters: weight changes, rectal temperature,
packed cell volumeltsl; haemoglobin concentration, total
and differential white blood cell counts[20J. Also clinical
signs were observed throughout the period of infection and
treatments. Survivability of the rats were also monitored and
recorded.
2.7. Statistical analysis
Data obtained were computed into means and analysed
using analysis of variance (ANOVA). The means were
separated at post hoc using Duncan's Multiple Range test[21]
at 95% confidence interval.
3. Results
3.1. Parasitaemia
An average pre patent period of 5 days was recorded in all
infected rats. Parasitaemia increased until day 7 PI when
the rats in groups A-D were treated. All rats in group E
died between day 25 and 32 PI (Table 1). The clinical signs
observed were anorexia, starry hair coat, cuddling, weakness
and depression. These signs disappeared gradually following
treatment in groups A- D while the signs remained in the
untreated group E in addition to the reluctance to move,
facial oedema, enlarged abdomen and death. The treated
rats remained aparasitaemic throughout the experiment. No
relapse of infection was recorded in any of the treatment
combinations.
3.2. Rectal temperature
The mean rectal temperature of infected rats was
significantly higher (P<0.05) in group E (infected untreated)
at days 14 and 21 PI than in the infected treated and
uninfected untreated groups (Table 2). However, there was a
significantly higher mean rectal temperature (P<0.05) of rats
in group B (day 28 P1) and group C (days 21, 42, 56 and 70
P1) than in the uninfected control and other treated groups.
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Table 1
Parasitaemia of T. brucei brucei infected rats treated with diminazene aceturate, and either levamisole or vitamin C combinations.
Days Group A Group B Group C Group D Group E Group F
0 0/5 0/5 0/5 0/5 0/5 0/5
7 5/5 5/5 5/5 5/5 5/5 0/5
14 0/5 0/5 0/5 0/5 5/5 0/5
21 0/5 0/5 0/5 0/5 5/5 0/5
28 0/5 0/5 0/5 0/5 2/2 0/5
35 0/5 0/5 0/5 0/5 0/0 0/5
42 0/5 0/5 0/5 0/5 0/0 0/5
49 0/5 0/5 0/5 0/5 0/0 0/5
56 0/5 0/5 0/5 0/5 0/0 0/5
63 0/5 0/5 0/5 0/5 0/0 0/5
70 0/5 0/5 0/5 0/5 0/0 0/5
77 0/5 0/5 0/5 0/5 0/0 0/5
Numerator: Number of rats positive; Denominator: Number infected and surviving.
Group A: Infected and treated with 3.5 mg/kg DA; Group B: Infected and treated with 3.5 mg/kg DA + 7.5 mg/kg levamisole; Group C: Infected 
and treated with 3.5 mg/kg DA + 100 mg/kg Vitamin C; Group D: Infected and treated with 3.5 mg/kg DA + 7.5 mg/kg levamisole + 100 mg/kg 
Vitamin C; Group E: Infected and untreated; Group F: Uninfected and untreated.
Table 2
Mean temperature 依 SEM (曟) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination with either 
levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 36.36依0.33a 36.84依0.22a 36.76依0.36a 36.44依0.16a   36.7依0.14a 36.60依0.18a
  7* 36.56依0.26a 36.52依0.51a 37.08依0.27a 37.08依0.39a 36.66依0.11a 36.33依0.26a
14 37.14依0.15ab 36.44依0.10e 37.62依0.22cd 37.26依0.08bc 37.74依0.07d 36.83依0.06a
21 37.02依0.32ab 36.92依0.12ab 37.06依0.17ab 37.00依0.15ab 37.26依0.22b 36.60依0.12a
28 36.82依0.07a 36.98依0.22ab 37.40依0.28b 37.12依0.09ab 36.98依0.17ab 36.70依0.14a
35 36.12依0.18a 36.88依0.24b 36.58依0.36ab 36.52依0.31ab   0.00依0.00b 35.90依0.13a
42 36.64依0.27a 37.06依0.16a 36.90依0.38a 36.80依0.27a   0.00依0.00a 36.63依0.10a
49 36.76依0.20ab 36.90依0.19ab 37.42依0.36bc 36.52依0.25a   0.00依0.00 36.45依0.21a
56 36.50依0.06a 36.80依0.25a 36.72依0.13a 36.68依0.12a   0.00依0.00 36.53依0.16a
63 36.68依0.20bc 36.80依0.11bc 37.24依0.31c 36.56依0.13ab   0.00依0.00 36.08依0.21a
70 36.64依0.12a 36.32依0.13a 36.62依0.10a 36.62依0.12a   0.00依0.00 36.53依0.15a
77 36.84依0.04c 36.54依0.08ab 37.20依0.18d 36.76依0.12c   0.00依0.00 36.40依0.10a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
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3.3. Proportional weight changes
There was a significant decrease (P<0.05) in the mean
proportional weight change in rats of group B (Table
3) when compared with other infected groups and the
uninfected control at day 14 (l days Pl). However, there was
a significantly lower <p<0.05) weight change in the infected
untreated group E, at day 28 PI, with subsequent death of all
rats in this group. Similarly, the proportional weight change
of rats in group B was significantly lower (P<0.05) than the
uninfected control at days 14,21,28,35,42 and 49 PI.
3.4. Packed cell Volume (PGV)
The PCV of rats in the infected groups was significantly
lower (P<0.05) than those of the uninfected untreated group F
at day 7 PI (fable 4). However, 14 days after treatment (day 21
PI) the mean PCV values of rats in group E was significantly
lower <p<0.05) than those of the uninfected control and other
treated groups. This continued till the death of all rats in
group E. There was a significantly lower (P<0.05) PCV of rats
in group A (DA only) than the other treated groups as well as
the uninfected control group at days 14,21,42,56 and 70 PT
whereas other treated groups (C and D) were not significantly
different <p>0.05) with the uninfected control group F.
3.5. Haemoglobin concentration (Hb)
The Mean Hb of all infected groups and the control were
not significant (P>0.05) at 7 days PI (Table 5). However,
the infected untreated control had significantly lower
Haemoglobin concentration <p<0.05) than the uninfected
untreated and other treated groups at day 14 PI (l days Pf),
This decrease continued for all rats in this group (group E)
until death of all rats in the group. However, the mean Hb of
rats in all treated groups continued to appreciate, although
they were significantly lower <p<0.05) than the uninfected
control.
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Table 3
Mean proportional body weight changes (g) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination 
with either levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 1.00依0.00a 1.00依0.00a 1.00依0.00 a 1.00依0.00 a 1.00依0.00 a 1.00依0.00 a
  7* 1.02依0.03a 1.01依0.01a 1.02依0.01 a 1.01依0.01 a 1.05依0.02 a 1.05依0.03 a  
14 1.02依0.02b 0.96依0.01c 1.04依0.02ab 1.03依0.01 b 1.09依0.02 a 1.08依0.02 a
21 1.03依0.02ab 0.97依0.02b 1.11依0.06 a 1.05依0.03ab 1.08依0.03 a 1.09依0.03 a
28 1.04依0.02a 0.98依0.02b 1.08依0.02 a 1.06依0.02 a 0.86依0.01c 1.10依0.03 a
35 1.05依0.02a 0.98依0.03b 1.08依0.02 a 1.10依0.01 a 0.00依0.00 1.11依0.02 a
42 1.03依0.02bc 1.02依0.03c 1.06依0.03abc 1.10依0.02ab 0.00依0.00 1.11依0.02 a
49 1.02依0.03bc 0.98依0.04c 1.05依0.03abc 1.08依0.02ab 0.00依0.00 1.11依0.02 a
56 0.99依0.02b 1.05依0.03ab 1.04依0.03ab 1.10依0.02 a 0.00依0.00 1.09依0.04 a
63 1.00依0.02c 1.04依0.03bc 1.05依0.03abc 1.11依0.02ab 0.00依0.00 1.12依0.02 a 
70 1.04依0.02bc 0.99依0.03c 1.08依0.03ab 1.11依0.02ab 0.00依0.00 1.15依0.03 a
77 1.02依0.02bc 0.96依0.03c 1.04依0.04bc 1.07依0.03ab 0.00依0.00 1.14依0.02 a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
Table 4
Mean packed cell volume (%) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination with either 
levamisole or vitamin C or both.
DAY Group A Group B Group C Group D Group E Group F
  0 44.60依1.69b 44.20依3.09b 44.40依1.94b 43.2依2.08b 53.80依1.46b 43.75依2.06a
  7* 37.60依1.96b 40.40依1.86ab 40.40依2.20ab 38.2依1.11b 37.80依1.39b 44.25依1.93a
14 34.40依1.60b 38.20依1.16b 35.80依2.27b 37.8依3.51b 37.80依2.94b 46.00依2.16a
21 40.60依1.21b 43.40依1.25ab 44.00依1.14ab 42.4依1.60ab 32.60依0.24c 45.75依2.17a
28 41.00依2.02b 45.60依0.93ab 44.60依1.63ab 41.6依2.73b 30.40依0.24c 47.75依0.63a
35 41.00依1.26a 43.60依2.54a 42.40依1.54a 39.8依1.43a   0.00依0.00 42.25依1.03a
42 40.60依0.93a 40.40依1.57a 44.60依0.98a 41.4依2.38a   0.00依0.00 43.00依0.91a
49 40.20依1.56b 41.00依1.52ab 40.40依0.68b 41.2依1.93ab   0.00依0.00 44.75依1.03a
56 41.00依1.30a 43.40依0.93a 40.60依0.93a 40.2依1.43a   0.00依0.00 42.75依2.46a
63 34.80依1.11b 37.80依1.50ab 36.20依1.77ab 36.4依1.81ab   0.00依0.00 40.00依2.04a
70 39.60依0.68a 42.20依1.32a 42.00依0.55a 42.4依1.69a   0.00依0.00 42.00依1.08a
77 41.20依0.49c 42.80依2.06bc 45.00依0.45ab 42.4依1.33bc   0.00依0.00 46.50依0.65a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
Table 5
Mean haemoglobin concentration (g/dL) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination with 
either levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 13.52依0.32bc 13.36依0.52c 14.30依0.28abc 15.26依0.38b 15.10依0.80b 14.90依0.26ab
  7* 15.66依0.91a 16.44依0.36a 13.88依0.88a 13.84依1.01a 14.16依0.89a 14.83依0.32a
14 11.60依0.58ab 14.14依0.96a 12.68依1.35a 13.02依0.91a   9.64依0.79b 13.98依0.39a
21 12.76依0.83b 13.18依0.49b 12.28依0.67b 11.46依0.39b   9.48依0.68c 15.65依0.93a
28 11.62依0.71a 13.52依0.32a 13.52依0.51a 13.46依1.24a   9.26依0.64b 13.43依0.83a
35 15.46依1.51b 13.64依0.85ab 13.70依0.96ab 11.62依1.07a   0.00依0.00 11.95依0.23a
42 12.94依0.41a 12.14依0.16a 13.14依0.63a 12.44依0.46a   0.00依0.00 13.33依0.32a
49 11.52依0.25a 11.62依0.77a 12.06依0.54ab 13.60依0.78b   0.00依0.00 11.78依0.14a
56 14.04依0.56a 12.86依0.50a 12.18依0.54a 13.60依0.85a   0.00依0.00 13.60依0.78a
63 12.36依0.51ab 13.76依1.14a 11.84依0.30b 11.18依0.58b   0.00依0.00 13.70依0.10a
70 12.12依0.78a 12.50依0.64a 13.30依0.54a 12.28依0.79a   0.00依0.00 13.78依0.24a
77 13.40依0.41a 12.18依0.55a 13.72依0.37a 12.78依0.76a   0.00依0.00 13.15依0.45a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
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Table 6
Mean total leukocyte count (伊103/mm3) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination with 
either levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 15.96依1.95a 15.34依1.85a 10.61依0.57a 13.13依1.96a 11.70依1.72a 11.03依1.02a
  7* 13.30依1.44b 17.38依1.13c   9.04依0.76a 10.09依1.57ab 10.12依1.36ab 12.73依1.17ab
14 10.08依0.44ab   7.04依0.57c   8.10依0.88bc   7.15依1.05c   8.04依1.12bc 12.38依0.94a
21 11.70依2.11a 15.21依2.26a 12.97依1.12a 13.93依1.68a   4.79依0.49b 13.59依1.56a
28 10.79依1.34a 17.86依1.67b 11.76依1.19a 11.37依1.60a   3.67依0.11c 10.68依2.66a
35 10.43依0.52b 12.25依0.69ab 10.85依0.10b 10.37依0.86b   0.00依0.00 13.81依0.96a
42   9.30依0.98b 12.52依1.09ab 14.67依2.68a   9.38依1.66b   0.00依0.00 12.30依1.15ab
49 13.15依2.28a 12.23依2.12a 12.52依2.27a   8.99依0.70a   0.00依0.00 13.03依1.55a
56 12.25依1.63a 11.91依1.62a 11.51依1.46a 11.89依1.26a   0.00依0.00 10.63依2.53a
63 13.25依0.78b 12.23依1.31ab 10.54依0.24b 11.38依0.30ab   0.00依0.00 12.00依0.99a
70 10.60依1.24a 12.30依1.41a 11.84依1.38a 10.66依0.96a   0.00依0.00 13.16依0.33a
77   8.40依0.67b 11.82依0.73a 10.84依1.27a 11.11依0.59a   0.00依0.00 12.50依0.66a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
Table 7
Mean absolute lymphocyte count (伊103/mm3) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination 
with either levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 8.29依2.33a 7.00依0.84a 6.17依0.97a 5.43依1.93a 5.24依0.57a 4.67依1.25a
  7* 7.46依1.53ab 9.31依0.83b 4.73依0.81a 4.94依1.38a 5.19依0.83a 5.63依0.44a
14 6.56依0.62a 2.95依0.26c 4.87依0.61ab 3.93依0.66bc 3.95依0.52bc 5.30依0.73ab
21 6.57依2.30ab 7.23依2.16ab 7.69依0.97a 7.92依1.19a 2.74依0.48b 5.75依0.55ab
28 6.85依1.08a 8.16依1.51a 8.16依1.08a 7.31依1.07a 1.48依0.08b 6.07依1.81a
35 7.45依0.44ab 6.49依0.26ab 7.85依0.40ab 6.17依0.86b 0.00依0.00 8.10依1.11a
42 6.15依1.12ab 5.19依0.66b 9.07依1.62a 4.65依1.28b 0.00依0.00 6.77依1.09ab
49 9.72依1.88a 8.62依2.32ab 7.07依1.89ab 4.67依0.47bc 0.00依0.00 6.88依0.84ab
56 9.05依0.96a 7.81依1.44a 7.72依1.40a 7.63依0.97a 0.00依0.00 6.05依1.44a
63 8.92依1.41a 6.82依0.74a 6.66依0.44a 6.74依0.51a 0.00依0.00 6.56依1.24a
70 6.98依1.05a 6.71依0.61a 7.49依1.30a 6.29依0.90a 0.00依0.00 6.70依0.79a
77 5.94依0.90a 7.63依0.53a 7.96依1.21a 7.16依0.41a 0.00依0.00 6.73依1.07a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
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3.6. Total leucocyte count (TLC)
There was a significantly lower TLC (P<O.05) in groups
Band D at day 7 PT when compared with the uninfected
untreated and other infected groups (Table 6). The
significantly lower TLC (P<O.05) seen in the infected
untreated group at day 14 PT when compared to other groups
continued till the death of all rats in that group. Apart from
the significantly higher (P<O.05) TLC in group B at day 21 PT
when compared to other groups and the uninfected control,
the TLC of all the treated groups were not significantly
different (P>O.05) with the control from day 28 PT till the end
of the experiment.
3.6.1. Absolute lymphocyte count (ALC)
There was a significantly higher ALC (P<O.05) in group B
than in other infected groups and the uninfected untreated
group at day 7 PI (Table 7). By day 14 PI there was a
significantly lower ALC (P<O.05) in group B than other
infected groups and the uninfected untreated group. By 21
days PI, there was a significantly lower (P<O.05) ALC in group
E than other treated groups and the uninfected control. This
decrease was observed till all the rats in group E died. There
was also a significantly lower ALC (P<O.05) in group D than
the uninfected untreated group. By day 56 post treatment all
treated groups were not significantly different (P>O.05) with
the uninfected untreated group.
3.6.2. Absolute neutrophil count (ANC)
There was a significantly lower ANC (P<O.05) in group C
at day 7 when compared to group B and the uninfected and
untreated group F (Table 8). At day 14 (7 days PT), there
was a significantly lower (P<O.05) ANC in all the infected
groups than the uninfected control group F. By day 21, the
ANC of the untreated control (group E) was significantly
lower (P<O.05) than all the untreated groups (A-D) and the
uninfected control. At day 35, there was a significantly lower
ANC (P<O.05) in groups A and C than other treated groups
and the uninfected control. By day 42, the ANC of group B
was significantly higher (P<O.05) than other treated groups
and the control. It was however observed that rats in group A
had a significantly lower ANC (P<O.05) than the other treated
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Table 8
Mean absolute neutrophil count (伊103/mm3) of rats infected with T. brucei brucei and treated with diminazene aceturate alone, or in combination 
with either levamisole or vitamin C or both.
Days Group A Group B Group C Group D Group E Group F
  0 6.55依1.45 6.90依1.38 3.25依0.62 6.19依1.65 5.27依1.50 4.92依0.68
  7* 4.75依0.67bc 6.94依0.81a 3.91依0.42c 4.67依0.66bc 4.63依0.72bc 6.63依0.70ab
14 3.24依0.40b 3.89依0.39b 2.84依0.51b 3.10依0.41b 3.87依0.73b 6.60依0.44a
21 4.99依1.72ab 7.72依0.85a 4.83依0.23ab 5.92依0.94a 1.97依0.12b 7.56依1.73a
28 3.75依0.50a 9.28依1.32b 3.46依0.65a 4.33依0.63a 2.14依0.03a 4.51依0.93a
35 2.71依0.42c 5.26依0.43a 2.88依0.42bc 4.11依0.70ab 0.00依0.00 5.02依0.32a
42 2.93依0.36bc 7.33依0.70d 5.30依1.17a 4.54依0.70ab 0.00依0.00 5.05依0.24a
49 3.22依0.83ab 3.43依0.37ab 5.20依1.44a 4.17依0.39ab 0.00依0.00 5.64依1.06a
56 2.99依0.78a 3.84依0.60a 3.47依0.55a 4.05依0.41a 0.00依0.00 4.45依1.17a
63 3.98依0.94a 5.14依0.65a 3.57依0.27a 4.27依0.35a 0.00依0.00 4.66依0.63a
70 3.09依0.26c 5.19依0.80ab 4.10依0.69bc 3.98依0.49bc 0.00依0.00 5.91依0.79a
77 2.19依0.40c 3.91依0.61ab 2.73依0.53bc 3.73依0.59bc 0.00依0.00 5.30依0.68a
Different superscript in a row indicates significant difference between the group mean at (P<0.05). *Treatment day.
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groups and uninfected control group at days 70 to 77 of the
experiment.
4. Discussion
Experimental infection of albino rats with T. brucei brucei
was successful. The parasites were seen in the blood of
infected rats from the 4th day PI with an average prepatent
period of 5 days. The parasitaemia, which increased
progressively, lead to death of all rats in the infected
untreated group between 25 and 32 days PI. Parasitaemia
in susceptible animals may be influenced by the number of
parasite inoculated, stressors such as nutrition/starvation,
intercurrent infections, host immune competence and
the pathogenicity of the strain of T. brucei brucei[221. The
prepatent period of 5 days contrasts with the findings
of Sewell and Brocklesbylzsl and Anene et a[[241 where
a prepatent period of 3-4 d was reported. However, the
findings agree with reports of Ezeokonkwo and Agu[251 in
rabbits, Seifertl261 and Anene et al[271 in dogs and Anene et
al[241 in rats. Following treatment, all the treated groups (A,
B, C and D) became aparastaemic 48 h post treatment and
remained so throughout the end of the experiment. However,
in group D parasites cleared in 40% of the rats 24 h PT and
by 48 hours PT all the parasites cleared. In other treated
groups, parasites cleared 48 hours PT. No relapse infection
was recorded in all the treatment groups. This contrasts with
the finding of Anene et al[241 who recorded relapse infection
by day 42 PI in rats treated with DA; but agrees with the
findings of Rani and Sureshlzsl who treated trypanosomosis
in Pomeranian dog with a single dose of DA. It is likely that
early treatment (between 3 and 7 days) after infection usually
lead to permanent cure whereas late treatment (day 14 or
later) PI lead to relapse. Thus, relapse infection observed
with early treatment may therefore be due to drug resistance
while relapse in late treatment could be due to reappearance
of parasites, which may have been sequestered in the brain
and therefore were inaccessible to the drugs[291. Treatment in
this work was done on day 7 post infection (early treatment)
and thus could be the reason why no relapse infection was
recorded all through the observation period.
The clinical signs of anorexia, pale mucous membrane,
pyrexia, rough hair coat, dullness, depression, emaciation,
swollen face and abdomen observed in the infected rats,
were similar to those in mice, dogs and rabbits infected with
T. brucei brucei[27,301 and in cattle infected with Trypanosoma
congolense[311. It is also consistent with the reports of
Onyeyili and Anikalazl; Biryomumaisho et a[[321; Obidike
et a[[341 and Eze et a[[351. Following treatment, the clinical
signs gradually disappeared showing that DA as well as the
combination treatments was effective in reversing these
SIgns.
Pyrexia, observed between day 7 and 14 of the experiment,
is a recognized clinical symptom of trypanosomos'is
in animals[27,35,361. This is due to stimulation of the
thermoregulatory centre of the hypothalamus by pyrogens
released during infection[371. The treatment given reversed
the pyrexia in the treated rats, hence, the return of
normal temperature values from day 21 PT as seen in this
experiment.
The significant decrease (P<O.05) in proportional weight
changes of rats observed in the infected untreated
group (Group E) is in accordance with other reports that
trypanosomosis cause loss of weightl361. Reduction in weight
gain had been reported by Holmes et al[381 and is thought
to be associated with anorexia and dullness seen with
the infection. However, following treatment, there was a
gradual increase in the mean proportional weight changes
in the treated groups when compared with the uninfected
and infected controls. Interestingly, rats in group C and D
(treated with DA and vitamin C; and DA, levamisole and
vitamin C respectively) showed an overall weight gain which
was marked in group D, while Group B (treated with DAand
levamisole) showed a significant decrease (P<O.05) which
did not last long in the course of the experiment. Evidently,
combining DA with levamisole and vitamin C gave the best
results in terms of weight gain. This may be useful during
Adieme Ijeoma Chekwube et al./Asian Pacific Journal of Tropical Medicine (2014)438-445444 ! i f ) 8-
convalescence.
Anaemia, reportedly the most prominent feature of animal
trypanosomosis[22,39] was seen as a significant reduction
<p<0.05) in the mean pev and Hb values of all infected
groups by days 7 and 14 PI respectively. The fall in rev
as observed in this study is consistent with the findings
of Ezeokonkwo[25], Obidike et a[[33] and Anene et a[[24J.
Many factors have been reported in the literature to be
responsible for these reductions in the packed cell volume,
Haemoglobin concentration and total red blood cell count
in trypanosomosis of livestock. The factors include a
depression of erythropoiesis[38], immunological mechanisms
and erythrophagocytosis, increased plasma volume and
haemodilution[22] as well as disorders of coagulation[41J.
The severity of anaemia has been shown to depend on the
level and duration of parasitaemia[42J. By 14th day PT, all
the treated groups recovered from the anaemia that resulted
from the infection and their pev and Hb concentration
values compared favourably with that of the uninfected
control except for Group A which still showed a significantly
lower pev (P<0.05) values than other treated groups and the
infected untreated group. It could be seen therefore, that
the pev of groups that received drug combinations were not
significantly different with the uninfected control group than
Group A (DA alone), with Group B showing the best return to
normal values.
Reduction in the TLe (leucopenia) in the infected untreated
implies that T. brucei brucei had an immunosuppressive
effect on the infected untreated rats leading to an impaired
immune defence mechanism and death of all the rats in that
group within 32 days of infection. Leucopenia as observed
in this work agrees with the finding of Ezeh et al[36] and
contrasted with Akpa et a[[29] who observed leucocytosis
in dogs infected with T. brucei brucei. The observed
leucocytosis in group B by 7 days PI could not be explained.
However, since this trend did not continue subsequently, it
may be due to individual difference. The increase in TLe was
very marked in Groups B and D by day 14 PT when compared
with the other treated groups. This could be as a result of
the effect of levamisole which was given to these two groups.
Kumar et al[43] reported that the immunostimulatory activity
of levamisole is due to its ability to effect the maturation of
leukocyte and stimulation of T-cell differentiation. Singla et
a[[44] also reported that an individual animal's response to
levamisole is dependent on the dose, timing and duration of
administration as well as the animal's immune status. The
early leucopenia observed in this study may be attributed to
lymphopenia and neutropenia in the infected groups (A,e, D
and E) with exception of Group B where lymphocytosis was
recorded. Abenga et al[45] observed early leucopenia due to
concomitant lymphopenia and neutropenia in Zebu cattle
infected with Trypanosoma vivax. The lymphopenia and
neutropenia noticed in the infected groups (A, e, D and E)
returned to normal 14 days post treatment when they showed
significant increases (p<0.05) than the uninfected untreated
group. Though the mean lymphocyte counts of groups e
and D significantly increased (p<0.05), the mean neutrophil
counts of groups Band D were not significantly different
(hO.05) with the uninfected control.
In conclusion, early treatment of trypanosomosis using
DA alone, and the combinations of either levamisole and
or vitamin e was able to effectively clear the parasites
from the blood of infected rats and also prevent relapse.
Furthermore, the indices of anaemia and cellular response
were better in rats treated with the drug combinations. Even
so, the cost benefit of such combination therapy should be
weighed against the value placed on such animals to be
recommended for use, given the rising incidence of repeat
treatments due to relapse infection.
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